Gene · 90
Papers2,859
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 2,859
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Palovarotene (Sohonos), a synthetic retinoid for reducing new heterotopic ossification in fibrodysplasia ossificans progressiva: history, present, and future. | JBMR Plus | 2025 | 39677926 | PubTator, text mining | PubMed |
| PET in neurotherapeutic discovery and development. | Neurotherapeutics | 2025 | 39665954 | PubTator, text mining | PubMed |
| Pharmacokinetics of Zilurgisertib With and Without Food from Single and Multiple Ascending Dose Phase 1 Studies in Healthy Adults. | Eur J Drug Metab Pharmacokinet | 2025 | 39652202 | PubTator, text mining | PubMed |
| ACVR1 mediates renal tubular EMT in kidney fibrosis via AKT activation. | Cell Signal | 2025 | 39586521 | PubTator, text mining | PubMed |
| Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib. | Clin Lymphoma Myeloma Leuk | 2025 | 39516087 | PubTator, text mining | PubMed |
| Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST-2 Landmark Analysis of Survival. | Eur J Haematol | 2025 | 39400386 | PubTator, text mining | PubMed |
| How I individualize selection of JAK inhibitors for patients with myelofibrosis. | Blood | 2025 | 39357058 | PubTator, text mining | PubMed |
| Fibrodysplasia ossificans progressiva emerges from obscurity. | Trends Mol Med | 2025 | 39299836 | PubTator, text mining | PubMed |
| Generalized Epileptic Seizures in Fibrodysplasia Ossificans Progressiva Harboring a Recurrent Heterozygous Variant of the ACVR1 Gene (R206H). | Case Rep Genet | 2024 | 39719967 | PubTator, text mining | PubMed |
| Investigating the Role of Primary Cilia and Bone Morphogenetic Protein Signaling in Periodontal Ligament Response to Orthodontic Strain In Vivo and In Vitro: A Pilot Study. | Int J Mol Sci | 2024 | 39684361 | PubTator, text mining | PubMed |
| Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of Momelotinib. | Cancers (Basel) | 2024 | 39682250 | PubTator, text mining | PubMed |
| The role of miRNAs as biomarkers in heterotopic ossification. | EFORT Open Rev | 2024 | 39620561 | PubTator, text mining | PubMed |
| Discovery of highly potent and ALK2/ALK1 selective kinase inhibitors using DNA-encoded chemistry technology. | Proc Natl Acad Sci U S A | 2024 | 39541346 | PubTator, text mining | PubMed |
| BMP2 and BMP7 cooperate with H3.3K27M to promote quiescence and invasiveness in pediatric diffuse midline gliomas. | Elife | 2024 | 39373720 | PubTator, text mining | PubMed |
| Challenges in the diagnosis of fibrodysplasia ossificans progressiva with the ACVR1 mutation (c.774G > C, p.R258S): a case report and review of literature. | Orphanet J Rare Dis | 2024 | 39350127 | PubTator, text mining | PubMed |
| Unlocking the Door for Precision Medicine in Rare Conditions: Structural and Functional Consequences of Missense ACVR1 Variants. | OMICS | 2024 | 39288033 | PubTator, text mining | PubMed |
| Fibrodysplasia ossificans progressiva complicated with post traumatic and infectious myositis ossificans in masseter: A case report. | Medicine (Baltimore) | 2024 | 39287296 | PubTator, text mining | PubMed |
| A pontine-specific axonal niche supports de novo gliomagenesis. | bioRxiv | 2024 | 39282464 | PubTator, text mining | PubMed |
| [A case of progressive ossifying myositis caused by ACVR1 gene mutation]. | Zhongguo Dang Dai Er Ke Za Zhi | 2024 | 39267512 | PubTator, text mining | PubMed |
| [JAK inhibitors for myelofibrosis: ruxolitinib and momelotinib]. | Rinsho Ketsueki | 2024 | 39231711 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/90/papers?page=6